HC Wainwright Has Bullish Estimate for ACXP FY2024 Earnings

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) – Analysts at HC Wainwright lifted their FY2024 earnings per share estimates for Acurx Pharmaceuticals in a report issued on Thursday, November 14th. HC Wainwright analyst E. Arce now forecasts that the company will earn ($0.89) per share for the year, up from their previous forecast of ($0.98). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q4 2024 earnings at ($0.18) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.59) EPS, FY2025 earnings at ($2.06) EPS, FY2026 earnings at ($2.87) EPS, FY2027 earnings at ($3.18) EPS and FY2028 earnings at ($3.35) EPS.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. During the same period in the prior year, the company posted ($0.24) earnings per share.

Acurx Pharmaceuticals Price Performance

Shares of Acurx Pharmaceuticals stock opened at $1.72 on Monday. The stock’s 50-day moving average is $1.95 and its 200-day moving average is $2.14. Acurx Pharmaceuticals has a one year low of $1.52 and a one year high of $5.28. The firm has a market cap of $29.05 million, a price-to-earnings ratio of -1.58 and a beta of -1.73.

Institutional Trading of Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Prospect Financial Services LLC grew its stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 6.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 295,075 shares of the company’s stock after acquiring an additional 16,975 shares during the period. Prospect Financial Services LLC owned 1.86% of Acurx Pharmaceuticals worth $561,000 at the end of the most recent quarter. 11.53% of the stock is currently owned by hedge funds and other institutional investors.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.